Concomitant analyses of intratumoral microbiota and genomic features reveal distinct racial differences in breast cancer
[ad_1]
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. Cancer J. Clin. 71, 7–33 (2021).
Kim, G. et al. The contribution of race to breast tumor microenvironment composition and disease progression. Front. Oncol. 10, https://doi.org/10.3389/fonc.2020.01022 (2020).
Lin, C.-H. et al. Contrasting epidemiology and clinicopathology of female breast cancer in Asians vs the US population. J. Natl Cancer Inst. 111, 1298–1306 (2019).
Morey, B. N. et al. Higher breast cancer risk among immigrant asian american women than among US-born Asian American women. Prev. Chronic Dis. 16, E20–E20 (2019).
Yap, Y.-S. et al. Insights into breast cancer in the east vs the west: a review. JAMA Oncol. 5, 1489–1496 (2019).
Danforth, D. N. Jr Disparities in breast cancer outcomes between Caucasian and African American women: a model for describing the relationship of biological and nonbiological factors. Breast Cancer Res. 15, 208 (2013).
Siddharth, S. & Sharma, D. Racial disparity and triple-negative breast cancer in African-American women: A multifaceted affair between obesity, biology, and socioeconomic determinants. Cancers (Basel) 10, https://doi.org/10.3390/cancers10120514 (2018).
Shavers, V. L. & Brown, M. L. Racial and ethnic disparities in the receipt of cancer treatment. J. Natl Cancer Inst. 94, 334–357 (2002).
Haynes-Maslow, L. et al. African American women’s perceptions of cancer clinical trials. Cancer Med. 3, 1430–1439 (2014).
Newman, L. A. et al. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J. Clin. Oncol. 24, 1342–1349 (2006).
Tammemagi, C. M., Nerenz, D., Neslund-Dudas, C., Feldkamp, C. & Nathanson, D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294, 1765–1772 (2005).
Hershman, D. et al. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J. Natl Cancer Inst. 95, 1545–1548 (2003).
Friebel-Klingner, T. M. et al. Risk factors for breast cancer subtypes among Black women undergoing screening mammography. Breast Cancer Res. Treat. 189, 827–835 (2021).
Akinyemiju, T. F., Pisu, M., Waterbor, J. W. & Altekruse, S. F. Socioeconomic status and incidence of breast cancer by hormone receptor subtype. Springerplus 4, 508 (2015).
Lund, M. J. et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res. Treat. 113, 357–370 (2009).
Carey, L. A. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492–2502 (2006).
Keenan, T. et al. Comparison of the genomic landscape between primary breast cancer in African American versus white women and the association of racial differences with tumor recurrence. J. Clin. Oncol. 33, 3621–3627 (2015).
Dietze, E. C., Sistrunk, C., Miranda-Carboni, G., O’Regan, R. & Seewaldt, V. L. Triple-negative breast cancer in African-American women: disparities versus biology. Nat. Rev. Cancer 15, 248–254 (2015).
Walsh, S. M., Zabor, E. C., Stempel, M., Morrow, M. & Gemignani, M. L. Does race predict survival for women with invasive breast cancer. Cancer 125, 3139–3146 (2019).
Deshmukh, S. K. et al. Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. Oncotarget 6, 11231–11241 (2015).
Govan, V. A. et al. Ethnic differences in allelic distribution of IFN-g in South African women but no link with cervical cancer. J. Carcinog. 2, 3 (2003).
Siddharth, S. et al. Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression. Elife 10, https://doi.org/10.7554/eLife.70729 (2021).
Hoskins, K. F., Danciu, O. C., Ko, N. Y. & Calip, G. S. Association of race/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women. JAMA Oncol. 7, 370–378 (2021).
Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973–980 (2020).
Sári, Z. et al. Indolepropionic acid, a metabolite of the microbiome, has cytostatic properties in breast cancer by activating AHR and PXR receptors and inducing oxidative stress. Cancers (Basel) 12, https://doi.org/10.3390/cancers12092411 (2020).
Ravnik, Z., Muthiah, I. & Dhanaraj, P. Computational studies on bacterial secondary metabolites against breast cancer. J. Biomol. Struct. Dyn. 39, 7056–7064 (2021).
Sári, Z. et al. Indoxylsulfate, a metabolite of the microbiome, has cytostatic effects in breast cancer via activation of AHR and PXR receptors and induction of oxidative stress. Cancers (Basel) 12, https://doi.org/10.3390/cancers12102915 (2020).
Kovács, T. et al. Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors. Sci. Rep. 9, 1300 (2019).
Kovács, P. et al. Lithocholic acid, a metabolite of the microbiome, increases oxidative stress in breast cancer. Cancers (Basel) 11, https://doi.org/10.3390/cancers11091255 (2019).
Parida, S. et al. A procarcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates notch and β-catenin axes. Cancer Discov. 11, 1138–1157 (2021).
Van der Merwe, M., Van Niekerk, G., Botha, A. & Engelbrecht, A. M. The onco-immunological implications of Fusobacterium nucleatum in breast cancer. Immunol. Lett. 232, 60–66 (2021).
Terrisse, S. et al. Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death Differ. 28, 2778–2796 (2021).
Shiao, S. L. et al. Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy. Cancer Cell 39, 1202–1213.e1206 (2021).
Baker, J. M., Al-Nakkash, L. & Herbst-Kralovetz, M. M. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas 103, 45–53 (2017).
Kwa, M., Plottel, C. S., Blaser, M. J. & Adams, S. The intestinal microbiome and estrogen receptor-positive female breast cancer. J. Natl Cancer Inst. 108, djw029 (2016).
Aguilera, M., Gálvez-Ontiveros, Y. & Rivas, A. Endobolome, a new concept for determining the influence of microbiota disrupting chemicals (MDC) in relation to specific endocrine pathogenesis. Front. Microbiol. 11, https://doi.org/10.3389/fmicb.2020.578007 (2020).
Grieneisen, L. et al. Gut microbiome heritability is nearly universal but environmentally contingent. Science 373, 181–186 (2021).
Goodrich, J. K. et al. Human genetics shape the gut microbiome. Cell 159, 789–799 (2014).
Hall, A. B., Tolonen, A. C. & Xavier, R. J. Human genetic variation and the gut microbiome in disease. Nat. Rev. Genet. 18, 690–699 (2017).
Smith, A. et al. Distinct microbial communities that differ by race, stage, or breast-tumor subtype in breast tissues of non-Hispanic Black and non-Hispanic White women. Sci. Rep. 9, 11940 (2019).
Thyagarajan, S. et al. Comparative analysis of racial differences in breast tumor microbiome. Sci. Rep. 10, 14116 (2020).
Urbaniak, C. et al. Microbiota of human breast tissue. Appl. Environ. Microbiol. 80, 3007–3014 (2014).
Urbaniak, C. et al. The microbiota of breast tissue and its association with breast cancer. Appl. Environ. Microbiol. 82, 5039–5048 (2016).
Hieken, T. J. et al. The microbiome of aseptically collected human breast tissue in benign and malignant disease. Sci. Rep. 6, 30751 (2016).
Haabeth, O. A. W. et al. Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat. Commun. 2, 240 (2011).
Shi, Y. et al. Integrative comparison of mRNA expression patterns in breast cancers from caucasian and Asian Americans with implications for precision medicine. Cancer Res. 77, 423–433 (2017).
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 109, 1721–1728 (2007).
Chen, C.-H. et al. Disparity in tumor immune microenvironment of breast cancer and prognostic impact: Asian versus western populations. Oncologist 25, e16–e23 (2020).
Lv, F. et al. Phase II study of pseudomonas aeruginosa-mannose-sensitive hemagglutinin in combination with capecitabine for HER2-negative metastatic breast cancer pretreated with anthracycline and taxane. J. Clin. Oncol. 32, 1053–1053 (2014).
Kisil, O. V., Efimenko, T. A. & Efremenkova, O. V. Looking back to Amycolatopsis: history of the antibiotic discovery and future prospects. Antibiotics (Basel) 10, 1254 (2021).
Matthies, C., Evers, S., Ludwig, W. & Schink, B. Anaerovorax odorimutans gen. nov., sp. nov., a putrescine-fermenting, strictly anaerobic bacterium. Int. J. Syst. Evolut. Microbiol. 50, 1591–1594 (2000).
Leveque, J. et al. Polyamines in human breast cancer and its relations to classical prognostic features: clinical implications. Anticancer Res. 19, 2275–2279 (1999).
Kingsnorth, A. N., Wallace, H. M., Bundred, N. J. & Dixon, J. M. Polyamines in breast cancer. Br. J. Surg. 71, 352–356 (1984).
Soda, K. The mechanisms by which polyamines accelerate tumor spread. J. Exp. Clin. Cancer Res. 30, 95 (2011).
Fang, Q., Feng, Y., Feng, P., Wang, X. & Zong, Z. Nosocomial bloodstream infection and the emerging carbapenem-resistant pathogen Ralstonia insidiosa. BMC Infect. Dis. 19, 334 (2019).
Maqbool, I. et al. Crude cell-free extract from deinococcus radiodurans exhibit anticancer activity by inducing apoptosis in triple-negative breast cancer cells. Front. Cell Dev. Biol. 8, https://doi.org/10.3389/fcell.2020.00707 (2020).
Lindner, R. et al. Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy. PLoS ONE 8, e71915 (2013).
Martin, D. N. et al. Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS ONE 4, e4531 (2009).
Poore, G. D. et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature 579, 567–574 (2020).
Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).
[ad_2]
Source link
